GLTO News and Press, Galecto Inc.

-- Company will trade on Nasdaq under trading symbol "DMRA" effective March 10, 2026 -- -- On track to submit IND or CTA for DMR-001 in mutant-calreticulin essential thrombocythemia and myelofibrosis in mid-2026, with two clinical proof-of-concept datasets expected mid-2027 -- -- Strong f...

BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company working to redefine care for people with hematologic disorders, today announced that it granted equity awards on March 2, 2026, to four newly-hired, non-executive employees. The inducement grants were...

BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company working to redefine care for people with hematologic disorders, today announced that company management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on...

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 7.7% to $1.81 on volume of 859,097,032 shares Signing Day Sports Inc. (SGN) rose 29.1% to $0.2735 on volume of 412,488,200 shares ChowChow Cloud International Holdings Limited (CHO...

BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced the closing of its previously announced underwritten public offerin...

2026-02-10 23:55:01 ET Read the full article on Seeking Alpha For further details see: Galecto prices $275M stock offering

BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced the pricing of its previously announced underwritten public offerin...

BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced that it has commenced an underwritten public offering of shares of ...

DMR-001, a potentially best-in-class mutant calreticulin (“mutCALR”) targeting monoclonal antibody, on track for expected IND submission, or equivalent, in mid-2026 with anticipated first-in-human dosing via subcutaneous administration Recent addition of deep hematology/oncology ...

2026-01-06 09:29:09 ET More on Galecto Galecto, Inc. (GLTO) M&A Call - Slideshow Seeking Alpha’s Quant Rating on Galecto Historical earnings data for Galecto Financial information for Galecto Read the full article on Seeking Alpha F...